

## RESULTS 1

### Sexual treated troubles n = 126 i.e. 20.5% of our cancer outpatients

- > **main request = erectile troubles 90.5%** (n=114)
- > **minor requests: lowering of desire (n=5), dysorgasmia (n=2), dysejaculation (n=2), penile pain (n=2), infertility (n=1)**

**1<sup>st</sup> group (AC) n = 615  
non selected cancer patients**

#### Concerned cancers

- > **116 urological (92%) = 99 various treated PC** (54 radical prostatectomy, 22 radiotherapy, 8 HIFU, 11 simple or active surveillance, 4 hormonotherapy), **11 bladder, 2 kidney, 2 testis** (1 for infertility) and **2 penile cancers**.
- > **10 (8%) non urological** = 1 male chest, 2 lymphoma, 1 throat, 2 rectal, 2 colon, 1 lung, 1 leukaemia.

- **Specific treatments: mainly PDE5 inhibitors (PDE5i) (n=50) and PGE1 intracavernous injections (ICI) (n=48)**, then by associations: PDE5i + vacuum (n=8), PDE5i + ICI (n=2) or rarely miscellaneous (n= 18)

#### Referral physicians

- > large majority of patients (n =113) = already followed by our service.
- > only 13 patients (10.3%) = **minority sent by other physicians**
- > our department = main territorial and one of regional sexo-andrological referent centre, this strong differences point up a **major inequality care access**.



## RESULTS 2

### Age : mean 70.6 varying from 48 to 91

• **CP treatment** : 70 radical prostatectomy; 18 HIFU; 38 radiotherapy; 62 (intermittent or not) hormonotherapy; 42 abstention or simple surveillance; 8 active surveillance; 8 waiting for radiotherapy, HIFU or radical prostatectomy.

• **Specific ED treatment: n = 97 (48%)** i.e. **only half our ED patients** including 43 PDE5i, 42 PGE1 ICI and 12 miscellaneous (vacuum 2, muse 1, ICI + vacuum 2).

#### Erectile capacity

**2<sup>nd</sup> group n = 246  
exclusive prostate cancer (CP) all age**

- > **no ED = 45 (18%)**
  - mean age: 67.8 and mean EHS: 3.7
  - CP treatment : 8 post-radical prostatectomy; 2 waiting for HIFU or radical prostatectomy; 1 post-radiotherapy; 1 intermittent hormonotherapy; 4 simple and 3 active surveillance.

> **ED (HES score < 3) = 201 (82%)** mean age = 73.7 and mean EHS: 1.9

• **Survey approval = a strong majority** i.e. **95%** agreed to be questioned and informed **even if no specific demand !**

#### Surprising findings in our 14 patients > 80 years (11 %)

- > **1 without ED + 13 with ED (93%)** : mean EHS = 1.3
- > **3 ED treatment** : 1 ICI + 2 PDE5i



## RESULTS 3

### PC treatment = clearly heterogeneous and centre dependant

- intermittent or not hormonotherapy (27), surveillance (20), HIFU (18), radiotherapy + 3 years hormonotherapy (17), hormonotherapy after failure 1<sup>st</sup> or 2<sup>nd</sup> treatment (15), radical prostatectomy (8), radiotherapy (8), waiting for treatment (3), radiotherapy after radical prostatectomy (2), brachytherapy (2), chemotherapy (2)

**3<sup>rd</sup> group n = 122 exclusive ageing  
prostate cancer (CP)**

#### Main observations

- as expected, **almost all have an ED (92.6%)** but, when **proactively** asked, these “old patients” are still really interested
- **a strong majority (90.2%) agrees to be questioned and to be informed about the possibility of specific care** (even if they don't use or demand it).
- **a non negligible minority (18.8%) uses** (regularly or not) **a pharmacological treatment** (12 PD5i = 12, ICI = 10, ICI+ vacuum = 1)
- **85 years = a limit** as all patient > 84 has an ED and no one wants or uses a treatment (only 2 disagree with the survey; 13/14 are interested by an information)
- in the « youngest » patients, **1/3 (37.7%) of the 75-79 and 20.5% of the 80-84 are treated or interested by an information or a treatment.**



Unexpected but unquestionable and strong survey agreement

Age	Cases	Mean HES	No ED HES >2 (%)	Treatment (%)	Demand (%) (treatment / information)	Survey agreement = strong (%)	Survey agreement = real (%)	Survey agreement = why not (%)	Survey agreement = no (%)
75-79	69	1.62	5 (7.1)	20* (29)	6 (8.7)	43 (62.3)	23 (33.3)	3	0
80-84	39	1.42	3 (7.7)	3** (7.7)	5 (12.8)	23 (59)	11 (28.2)	4	1
85-89	12	1.45	1 (8.3)	0	0	7 (58.3)	3 (25)	1	1
90	2	1	0	0	0	-	-	2	-
	122	1.53	9 (7.4)	23 (18.8)	11 (9)	73 (59.8)	37 (30.3)	10 (8.2)	2 (1.6)

## CONCLUSIONS

In spite of several limitations, our observational surveys in **selected male outpatient samples** (n = 983 in daily real-life consultation of a non academic hospital) show **5 facts** :

- 1. a minority (20.5%) really benefit from specific care** concerning: a) mainly ED (90%), b) prostate cancer (PC) (79%), c) pharmacological treatments (89%)
- 2. reduced number of non urological cancers (8%) = real inequality of specific care access** (given to the prevalence of sexual problems in non urological cancers and to the fact that the urologists are the main male organic referent specialist)
- 3. if 82% all age prostate cancer patients have an ED, only half (48%) have a treatment .**
- 4. strong impact of health professional attitude** : if **proactively asked**, almost all PC patients want either specific information or treatment... even the older ones.
- 5. paradoxical situation concerning the reality of sexual complaint** in our consulting PC population as a whole :
  - **too often over-estimated in younger patients** as 50% < 70 years already has either sexual problems before any CP treatment or are not really interested in or motivated for a treatment
  - vs. **too often under-estimated in older patients** as a non negligible proportion (almost one third) remains either interested in or asking at least for an information